FR2724320B1
(fr)
|
1994-09-13 |
1996-12-20 |
Transgene Sa |
Nouvel implant pour le traitement des maladies acquises
|
IL127193A
(en)
|
1996-05-22 |
2006-10-31 |
Viventia Biotech Inc |
Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments and use thereof for the prophylaxis and detection of cancers
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
US20030095967A1
(en)
|
1999-01-25 |
2003-05-22 |
Mackay Fabienne |
BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
|
DK1210425T4
(en)
|
1999-08-17 |
2015-08-10 |
Apotech R & D Sa |
BAFF receptor (BCMA), an immunoregulatory agent
|
AU2001261557B2
(en)
|
2000-05-12 |
2005-06-30 |
Amgen Inc. |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
AU2002238052A1
(en)
|
2001-02-20 |
2002-09-04 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
JP2003111595A
(ja)
|
2001-06-25 |
2003-04-15 |
Kyogo Ito |
腫瘍抗原
|
US20080267965A1
(en)
|
2002-02-21 |
2008-10-30 |
Kalled Susan L |
Use of Bcma as an Immunoregulatory Agent
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
ATE455127T1
(de)
|
2003-05-31 |
2010-01-15 |
Micromet Ag |
Humane anti-humane cd3-bindungsmoleküle
|
KR20120125634A
(ko)
|
2003-10-16 |
2012-11-16 |
마이크로메트 에이지 |
다중특이적 탈면역화된 cd3-바인더
|
EP1675609A1
(en)
|
2003-10-20 |
2006-07-05 |
Biogen Idec MA Inc. |
Therapeutic regimens for baff antagonists
|
US7947805B2
(en)
|
2004-12-23 |
2011-05-24 |
Merck Serono S.A. |
BCMA polypeptides and uses thereof
|
CA2597924C
(en)
|
2005-02-15 |
2018-10-02 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
KR20080090441A
(ko)
|
2005-12-21 |
2008-10-08 |
메디뮨 엘엘씨 |
Epha2 bite 분자 및 이의 용도
|
BRPI0713426A2
(pt)
|
2006-06-14 |
2012-10-09 |
Macrogenics Inc |
métodos de tratar, diminuir a progressão, ou melhorar um ou mais sintomas de um distúrbio, e de prevenir ou retardar o inìcio de um distúrbio
|
KR101578940B1
(ko)
|
2007-01-24 |
2015-12-18 |
교와 핫꼬 기린 가부시키가이샤 |
이펙터 활성이 증강된 유전자 재조합 항체 조성물
|
RS52888B
(en)
|
2007-03-27 |
2014-02-28 |
Zymogenetics Inc. |
COMBINATION OF BLYS INHIBITION AND MYPHOPHENOLATE MOFETILE FOR THE TREATMENT OF AUTOMMUNE DISEASE
|
US8460647B2
(en)
|
2007-04-20 |
2013-06-11 |
Amgen Inc. |
Pre-ligand assembly domain of the IL-17 receptor
|
CN102164961B
(zh)
|
2008-10-01 |
2014-04-16 |
安进研发(慕尼黑)股份有限公司 |
种间特异性PSCAxCD3、CD19xCD3、C-METxCD3、内皮唾液酸蛋白xCD3、EpCAMxCD3、IGF-1RxCD3或FAPαxCD3双特异性单链抗体
|
CN102482347B
(zh)
|
2009-01-12 |
2017-04-26 |
希托马克斯医疗有限责任公司 |
修饰抗体组合物及其制备和使用方法
|
PT2406284T
(pt)
|
2009-03-10 |
2016-09-29 |
Biogen Ma Inc |
Anticorpos anti-bcma
|
US9273283B2
(en)
*
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
PT2552959T
(pt)
|
2010-03-26 |
2017-04-21 |
Memorial Sloan Kettering Cancer Center |
Anticorpos para muc16 e métodos de utilização dos mesmos
|
EP2611834B1
(en)
|
2010-09-01 |
2018-03-07 |
Biogen MA Inc. |
Rapid generation of anti-idiotypic antibodies
|
US20130273055A1
(en)
|
2010-11-16 |
2013-10-17 |
Eric Borges |
Agents and methods for treating diseases that correlate with bcma expression
|
RU2018108836A
(ru)
|
2011-02-04 |
2019-03-14 |
Дженентек, Инк. |
ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
|
WO2012118622A1
(en)
|
2011-02-19 |
2012-09-07 |
Baylor Research Institute |
Diagnostic and therapeutic uses for b cell maturation antigen
|
TWI803876B
(zh)
|
2011-03-28 |
2023-06-01 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
US20130101599A1
(en)
|
2011-04-21 |
2013-04-25 |
Boehringer Ingelheim International Gmbh |
Bcma-based stratification and therapy for multiple myeloma patients
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
LT3415531T
(lt)
|
2011-05-27 |
2023-09-25 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) – surišantys baltymai
|
EP3559049A4
(en)
|
2011-10-28 |
2019-12-04 |
Teva Pharmaceuticals Australia Pty Ltd |
POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
SI2794658T1
(sl)
|
2011-12-19 |
2017-05-31 |
Synimmune Gmbh |
Bispecifična molekula protitelesa
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
EP2822597A1
(en)
|
2012-03-09 |
2015-01-14 |
UCL Business Plc. |
Chemical modification of antibodies
|
BR112015000638A2
(pt)
|
2012-07-13 |
2017-08-08 |
Univ Pennsylvania |
sequência de ácido nucleico isolada, célula, métodos para estimular uma resposta imune mediada pela célula t e uma população de célula alvo ou tecido em um mamífero, para provimento de imunidade antitumor em um mamífero, para tratamento de um mamífero que tenha uma doença, distúrbio ou condição associado com uma expressão elevada de um antígeno de tumor
|
EP2953972B1
(en)
|
2013-02-05 |
2020-07-08 |
EngMab Sàrl |
Method for the selection of antibodies against bcma
|
EP3019622A4
(en)
|
2013-07-12 |
2017-06-14 |
Zymeworks Inc. |
Bispecific cd3 and cd19 antigen binding contructs
|
JP2016539929A
(ja)
|
2013-10-25 |
2016-12-22 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
免疫療法のためのポリクローナルγδT細胞
|
EP3102681B1
(en)
*
|
2014-02-07 |
2023-10-04 |
McMaster University |
Trifunctional t cell-antigen coupler and methods and uses thereof
|
EP3593812A3
(en)
*
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
WO2016166139A1
(en)
*
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
US11059880B2
(en)
*
|
2015-06-30 |
2021-07-13 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
|
KR20180038560A
(ko)
|
2015-08-28 |
2018-04-16 |
아뮤닉스 오퍼레이팅 인코포레이티드 |
키메라 폴리펩티드 조립체와 이의 제조 및 사용 방법
|
US20210206826A1
(en)
|
2015-11-19 |
2021-07-08 |
The Regents Of The University Of California |
Conditionally repressible immune cell receptors and methods of use thereof
|
MA43567A
(fr)
|
2015-12-15 |
2018-11-14 |
Amgen Inc |
Anticorps pacap et leurs utilisations
|
EP3493827A4
(en)
|
2016-08-04 |
2020-02-26 |
Memorial Sloan-Kettering Cancer Center |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
|
CN108250302A
(zh)
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多功能蛋白质
|
WO2019071358A1
(en)
|
2017-10-12 |
2019-04-18 |
Mcmaster University |
Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
MX2021000541A
(es)
|
2018-07-17 |
2021-08-16 |
Triumvira Immunologics Usa Inc |
Acoplador de celula t-antigeno con varias optimizaciones de constructo.
|
JP2022523749A
(ja)
|
2019-02-01 |
2022-04-26 |
クレージュ メディカル カンパニー,リミテッド |
Tcr融合タンパク質およびtcr融合タンパク質を発現する細胞
|
CN116744948A
(zh)
|
2020-11-06 |
2023-09-12 |
麦克马斯特大学 |
包含t细胞抗原偶联物的细胞及其用途
|
EP4347660A1
(en)
|
2021-06-01 |
2024-04-10 |
Triumvira Immunologics USA, Inc. |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|